Our previous study of HDMP and Rtx combination in relapsed high-risk CLL, including TP53 dysfunction, demonstrated efficacy with an overall response rate (ORR) of 62% [3]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.